TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26566655

Group type: EXPERIMENTAL
Intervention: EpCAM-based flow cytometry
Number of subjects: 29

Group type: COMPARATOR
Intervention: CSF cytology
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cell count or biochemical parameters in CSF
Number of subjects: 29
Study: 26566914

Group type: EXPERIMENTAL
Intervention: Genetic testing for the m.3243A>G MELAS mutation
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Clinical and cerebral MRI features review
Number of subjects: 238
Study: 26566980

Group type: EXPERIMENTAL
Intervention: Families SHARE workbook
Number of subjects: 100
Study: 26567113

Group type: EXPERIMENTAL
Intervention: [(64)Cu]DOTA-patritumab (9.0 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: [(64)Cu]DOTA-patritumab
Number of subjects: 8
Study: 26567120

Group type: EXPERIMENTAL
Intervention: Antihypotensive therapy
Number of subjects: 367

Group type: COMPARATOR
Intervention: No antihypotensive therapy
Number of subjects: 367
Study: 26567259

Group type: EXPERIMENTAL
Intervention: NeuroAiD (MLC601, MLC901)
Number of subjects: 2000
Study: 26567860

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous glucose infusion (IVGI)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Incretin effect calculation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Proinflammatory cytokines measurement
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Endogenous response of GIP and glucagon
Number of subjects: 8
Study: 26568466

Group type: EXPERIMENTAL
Intervention: 3-day treatment (15 mg/m² every 8 hours for three consecutive days/cycle/6 weeks)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 5-day treatment (20 mg/m² once daily on days 1-5/cycle/4 weeks)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Both treatment groups (3-day and 5-day)
Number of subjects: 135
Study: 26568833

Group type: EXPERIMENTAL
Intervention: Copeptin levels in patients with HFPEF
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Log copeptin
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: NT-proBNP correlation
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Diastolic dysfunction assessment
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Composite end point of all-cause mortality or HF hospitalisation
Number of subjects: 86
Study: 26568832

Group type: EXPERIMENTAL
Intervention: Congenital heart disease (CHD) group
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Intelligence assessment in CHD group
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Alertness assessment in CHD group
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Executive functions (EF) assessment in CHD group
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Memory assessment in CHD group
Number of subjects: 365

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 365
Study: 26569533

Group type: EXPERIMENTAL
Intervention: Elevated depressive symptoms
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Continuous severity of depressive symptoms
Number of subjects: 89
Study: 26571268

Group type: EXPERIMENTAL
Intervention: Bee venom treatment (subchronic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single injection of bee venom
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apamin (blocker of SK channels)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CyPPA (positive modulator of SK channels)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bee venom
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (neuroleptic treatment and 6-hydroxydopamine injection)
Number of subjects: 0
Study: 26571311

Group type: EXPERIMENTAL
Intervention: rSm14/GLA-SE vaccine (50 μg rSm14 with 10 μg GLA-SE, intramuscularly, three doses with 30-day intervals)
Number of subjects: 20
Study: 26572233

Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26572865

Group type: EXPERIMENTAL
Intervention: Anonymous HIV testing followed by confidential care linkage
Number of subjects: 0
Study: 26573078

Group type: EXPERIMENTAL
Intervention: DPYD*2A genotype-guided dosing (initial dose reduction of ≥ 50%)
Number of subjects: 2038

Group type: EXPERIMENTAL
Intervention: DPYD*2A genotype-guided dosing
Number of subjects: 2038

Group type: COMPARATOR
Intervention: Screening for DPYD*2A
Number of subjects: 2038
Study: 26573139

Group type: EXPERIMENTAL
Intervention: IMRT/IGRT with 50 Gy in 2 Gy single fractions (5 fractions per week)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: IMRT/IGRT
Number of subjects: 50
Study: 26573577

Group type: EXPERIMENTAL
Intervention: Prolim® stent
Number of subjects: 204
Study: 26573686

Group type: EXPERIMENTAL
Intervention: Equimolar mixture of oxygen and nitrous oxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other analgesic drugs
Number of subjects: 0
Study: 26573827

Group type: EXPERIMENTAL
Intervention: Shrinkage Estimator (SHE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probability Tree Estimator (PTE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum Likelihood Estimator (MLE)
Number of subjects: 0
Study: 26574583

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (300 µg PM(2.5)/m(3))
Number of subjects: 18

Group type: COMPARATOR
Intervention: Filtered air (control)
Number of subjects: 18
Study: 26575422

Group type: EXPERIMENTAL
Intervention: AvidinOX-anchored biotinylated Cetuximab (bCet)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Intra-tumor injection of AvidinOX with low dose bCet
Number of subjects: 1
Study: 26575452

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 0
Study: 26576059

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (15-35 mg/kg/day)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Higher fetal hemoglobin responses to hydroxyurea
Number of subjects: 383
Study: 26576546

Group type: EXPERIMENTAL
Intervention: COMT Met (158) allele
Number of subjects: 100

Group type: COMPARATOR
Intervention: Val (158) /Val (158) homozygotes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: COMT Val (158) Met polymorphism
Number of subjects: 100
Study: 26576744

Group type: EXPERIMENTAL
Intervention: Asthma cohorts (mild, moderate, severe)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Severe asthma cohort
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Asthma control questionnaire-7 (ACQ7) scores
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Induced sputum eosinophils
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: FENO and blood eosinophils
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Clinical and biomarker characteristics in asthmatics
Number of subjects: 188
Study: 26577132

Group type: EXPERIMENTAL
Intervention: Smart infusion pumps (SIP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Quick change technique (QC)
Number of subjects: 50
Study: 26577301

Group type: EXPERIMENTAL
Intervention: Permanent iodine-125 seed implantation (PI)
Number of subjects: 2160

Group type: COMPARATOR
Intervention: PI combined with external beam radiation therapy (PI + EBRT)
Number of subjects: 2160
Study: 26577754

Group type: EXPERIMENTAL
Intervention: Etonogestrel (ENG) implant
Number of subjects: 52
Study: 26578201

Group type: EXPERIMENTAL
Intervention: Pre-hospital morphine use
Number of subjects: 2438
Study: 26578401

Group type: EXPERIMENTAL
Intervention: Breast Cancer Index (BCI) genomic classification
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Pre-test anxiety and decision conflict measures
Number of subjects: 96
Study: 26578722

Group type: EXPERIMENTAL
Intervention: Everolimus (30 mg weekly) with Carboplatin (area under the curve 6) and Paclitaxel (200 mg/m²) every 3 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Everolimus combined with Carboplatin and Paclitaxel
Number of subjects: 45
Study: 26578731

Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion (HAI) with triplet chemotherapy (irinotecan 180 mg/m², oxaliplatin 85 mg/m², 5-fluorouracil 2800 mg/m²) and systemic cetuximab (500 mg/m²) every 14 days.
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion (HAI) with triplet chemotherapy and systemic cetuximab.
Number of subjects: 64
Study: 26578849

Group type: EXPERIMENTAL
Intervention: Dabigatran 220 mg once daily
Number of subjects: 4374

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 4374
Study: 26579222

Group type: EXPERIMENTAL
Intervention: Breathing through N95-mask materials
Number of subjects: 20
Study: 26579227

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 0
Study: 26579524

Group type: EXPERIMENTAL
Intervention: Health at Every Size(®)-based intervention
Number of subjects: 30
Study: 26579723

Group type: EXPERIMENTAL
Intervention: Sheehan Irritability Scale (SIS)
Number of subjects: 586

Group type: COMPARATOR
Intervention: Citalopram (inadequate response)
Number of subjects: 586
Study: 26580449

Group type: EXPERIMENTAL
Intervention: Community-based randomized intervention trial designed to promote breast and cervical cancer screening
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Living with a partner
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: High social support
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Higher worry
Number of subjects: 421
Study: 26580968

Group type: EXPERIMENTAL
Intervention: Cardiovascular prevention program in Sollentuna
Number of subjects: 56589
Study: 26581135

Group type: EXPERIMENTAL
Intervention: 60 Gy intensity modulated radiation therapy with concurrent weekly intravenous cisplatinum (30 mg/m(2))
Number of subjects: 43
Study: 26581137

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) with a prescribed dose of 48 Gy at the isocenter in 4 fractions
Number of subjects: 164
Study: 26581381

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (sleeve gastrectomy, proximal RYGB, distal RYGB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal-weight and less-obese subjects (control)
Number of subjects: 0
Study: 26581547

Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg once daily
Number of subjects: 27
Study: 26582138

Group type: EXPERIMENTAL
Intervention: Internet-based patient-provider communication (IPPC) service
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Comparison with other studies using CFIR
Number of subjects: 17
Study: 26582161

Group type: EXPERIMENTAL
Intervention: Papillary leakage present
Number of subjects: 59

Group type: COMPARATOR
Intervention: No papillary leakage
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Normal IOP
Number of subjects: 59

Group type: COMPARATOR
Intervention: Secondary glaucoma
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Secondary glaucoma with optic disc leakage
Number of subjects: 59
Study: 26582805

Group type: EXPERIMENTAL
Intervention: Continuous intraperitoneal insulin infusion (CIPII)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Subcutaneous (SC) insulin therapy
Number of subjects: 183
Study: 26582853

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% ACB with 20 ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine 1% ACB with varying volumes (5 ml, 10 ml, 15 ml, 20 ml)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% ACB
Number of subjects: 40
Study: 26583301

Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of relaxin over 48 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxin
Number of subjects: 0
Study: 26583503

Group type: EXPERIMENTAL
Intervention: High-definition white light (WL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Narrow band imaging with magnification (NBI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chromoendoscopy (CE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High degrees of histologic inflammation with WL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High degrees of histologic inflammation with CE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chromoendoscopy (CE) added to WL
Number of subjects: 0
Study: 26583585

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (BS)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (14 nonobese, nondiabetic subjects)
Number of subjects: 118
Study: 26584600

Group type: EXPERIMENTAL
Intervention: Siblings of patients with advanced adenomas (exposed)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Siblings of subjects with normal findings (unexposed)
Number of subjects: 600
Study: 26584601

Group type: EXPERIMENTAL
Intervention: Symptom score of 20
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Symptom score of 15
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Symptom score as a continuous variable
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Clinical remission defined as symptom score <20
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Endoscopic remission defined as absence of white exudates, moderate or severe rings, strictures, or combination of furrows and edema
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Histologic remission defined as peak count of <20 eosinophils/mm(2)
Number of subjects: 269
Study: 26584760

Group type: EXPERIMENTAL
Intervention: Resting state EEG band power measures
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Test-retest correlation of EEG band power measures
Number of subjects: 42
Study: 26584787

Group type: EXPERIMENTAL
Intervention: Subjective Global Assessment (SGA)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Malnutrition Inflammation Score (MIS)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Kidney Disease Quality of Life Short Form 1.3
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Nutrition-related tests (8 total)
Number of subjects: 489
Study: 26585432

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for 21 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulmonary exacerbation score and lung function assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assessment of bacterial density
Number of subjects: 0

Group type: COMPARATOR
Intervention: Absolute neutrophil counts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sputum inflammatory markers
Number of subjects: 0
Study: 26585508

Group type: EXPERIMENTAL
Intervention: LGE CMR examination
Number of subjects: 235
Study: 26585609

Group type: EXPERIMENTAL
Intervention: Colonoscopy screening
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Home stool test (HST)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Overall CRC screening uptake
Number of subjects: 453
Study: 26586415

Group type: EXPERIMENTAL
Intervention: NCI MATCH trial intervention (molecular analysis for therapy choice)
Number of subjects: 0
Study: 26586418

Group type: EXPERIMENTAL
Intervention: Fitbit physical activity tracker and website intervention for 16 weeks
Number of subjects: 25
Study: 26587282

Group type: EXPERIMENTAL
Intervention: iStent implantation and cataract surgery (combined group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cataract surgery alone (control group)
Number of subjects: 36
Study: 26587949

Group type: EXPERIMENTAL
Intervention: Attending radiologists
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Senior residents
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: 2nd-year residents
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: 1st-year residents
Number of subjects: 199
Study: 26588924

Group type: EXPERIMENTAL
Intervention: ibrutinib 420 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ibrutinib 560 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ibrutinib 140 mg and 280 mg (single-dose phase)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ibrutinib 420 mg (multiple-dose phase)
Number of subjects: 15
Study: 26589752

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of allogeneic mesenchymal stromal cells (MSCs) at a median dose of 2.7 × 10(6) cells/kg/infusion, range 1.3-4.5, given weekly for 2 to 5 weeks, in addition to standard rabbit ATG and cyclosporine.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard rabbit ATG and cyclosporine (control group).
Number of subjects: 9
Study: 26589907

Group type: EXPERIMENTAL
Intervention: Elevated transpulmonary gradient
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance-derived right ventricular remodeling
Number of subjects: 0
Study: 26589963

Group type: EXPERIMENTAL
Intervention: Canakinumab treatment in SJIA patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active AOSD prior to canakinumab treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 0
Study: 26590174

Group type: EXPERIMENTAL
Intervention: Intravenous abatacept (∼10 mg/kg) plus MTX for 24 weeks
Number of subjects: 89
Study: 26590194

Group type: EXPERIMENTAL
Intervention: Genetic risk factors (SNPs) related to BMP7 (rs75161997)
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Genetic risk factors (SNPs) related to PROX1-AS1 (rs1891059)
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Genetic risk factors (SNPs) related to GRID2 (rs34144324)
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Meta-analysis of BMP7 and PROX1-AS1 variants (rs75161997 and rs1891059)
Number of subjects: 899
Study: 26590773

Group type: EXPERIMENTAL
Intervention: Intestinal microbiota influence
Number of subjects: 0
Study: 26590912

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 448
Study: 26590963

Group type: EXPERIMENTAL
Intervention: Thoracic endovascular aortic repair (TEVAR) with left subclavian artery coverage
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: TEVAR
Number of subjects: 11
Study: 26593973

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (33 ± 1 °C)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normothermia (48 hours after hypothermia)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia and normothermia
Number of subjects: 22
Study: 26595305

Group type: EXPERIMENTAL
Intervention: IBS patients
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study: 26595440

Group type: EXPERIMENTAL
Intervention: Ready-to-eat cereal (RTEC) consumers
Number of subjects: 367442

Group type: EXPERIMENTAL
Intervention: Total fiber intake among RTEC consumers
Number of subjects: 367442
Study: 26595450

Group type: EXPERIMENTAL
Intervention: 3-drug regimen (ledipasvir, sofosbuvir, GS-9451) for 4 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 4-drug regimen (ledipasvir, sofosbuvir, GS-9451, GS-9669) for 4 weeks
Number of subjects: 50
Study: 26595611

Group type: COMPARATOR
Intervention: Lactation intensity (exclusive lactation, mostly lactation, mostly formula or mixed/inconsistent)
Number of subjects: 1035

Group type: COMPARATOR
Intervention: Lactation duration (greater than 0 to 2 months, greater than 2 to 5 months, greater than 5 to 10 months, greater than 10 months)
Number of subjects: 1035
Study: 26596767

Group type: EXPERIMENTAL
Intervention: Semi-automated volumetric segmentation tools
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Validation by neuroradiologist and general radiologist
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Exportation of data
Number of subjects: 21
Study: 26596948

Group type: EXPERIMENTAL
Intervention: 3D regimen (ombitasvir-paritaprevir-ritonavir) with sofosbuvir
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 2D regimen (ombitasvir-paritaprevir-ritonavir) with sofosbuvir
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sofosbuvir alone
Number of subjects: 32
Study: 26597091

Group type: EXPERIMENTAL
Intervention: MeTree web-based health risk assessment tool
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enrollment rate of clinics, providers, and patients
Number of subjects: 20
Study: 26597180

Group type: EXPERIMENTAL
Intervention: Dasotraline 4 or 8 mg/day
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Dasotraline (various doses from 0.2 to 36 mg)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Dasotraline
Number of subjects: 395
Study: 26597443

Group type: EXPERIMENTAL
Intervention: Cetuximab in combination with 5-fluorouracil (5FU) and mitomycin C (MMC) during chemoradiotherapy (CRT)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) 800 mg/m(2) on RT days 1-4 and 29-32 and mitomycin C (MMC) 8 mg/m(2) on days 1 and 29
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Standard doses of cetuximab
Number of subjects: 13
Study: 26597653

Group type: EXPERIMENTAL
Intervention: Topical mosquito repellent distribution scheme (2-weekly bottle exchange programme)
Number of subjects: 135
Study: 26597824

Group type: EXPERIMENTAL
Intervention: OHyperT (orthostatic hypertension) group (n=275)
Number of subjects: 972

Group type: COMPARATOR
Intervention: Orthostatic normotension group (n=540)
Number of subjects: 972

Group type: COMPARATOR
Intervention: OHypoT (orthostatic hypotension) group (n=157)
Number of subjects: 972
Study: 26597937

Group type: EXPERIMENTAL
Intervention: Web-based educational intervention providing information related to chronic low back pain in different formats.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment provided by family physician.
Number of subjects: 0
Study: 26597976

Group type: EXPERIMENTAL
Intervention: General health checks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 26598545

Group type: EXPERIMENTAL
Intervention: HER2-PET/CT
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: early FDG-PET/CT
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Combination of HER2-PET/CT and FDG-PET/CT
Number of subjects: 56
Study: 26599244

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI)
Number of subjects: 17
Study: 26599344

Group type: EXPERIMENTAL
Intervention: EGFR mutation analysis
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: EGFR active mutation analysis
Number of subjects: 747

Group type: COMPARATOR
Intervention: Tobacco use analysis
Number of subjects: 747

Group type: COMPARATOR
Intervention: Regional lymph nodes involvement analysis
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Smoking status analysis
Number of subjects: 747